A new project aimed at expanding legal access to psilocybin while compiling data on its clinical efficacy and safety has been a new subject of interest among the psychedelic community.
On Thursday, TheraPsil formally announced the launch of Project Solace on social media — a new campaign that the non-profit organization describes as the world’s largest medical psilocybin access and data project. Project Solace will be led in collaboration with Drug Science, a company dedicated to researching and assessing scientific evidence related to psychoactive drugs in the UK.
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) also announced that it would be participating in the new pilot project endeavour.
Today @TheraPsil launched Project Solace, the world's largest medical psilocybin access + data project. We're proud to support the project as a Health Canada-licensed psilocybin producer. https://t.co/yk4oB4PnoB
— Filament Health (@FilamentHealth) July 28, 2022
Read more: Sage Institute receives grant to help continue its psychedelic therapy in California
Read more: Psilocybin and craft cannabis farmers to gather in B.C.
“We are grateful for Filament Health’s support of Project Solace. There are a limited number of Health Canada-approved psilocybin suppliers, so Filament’s participation greatly enhances the likelihood of patient access to much-needed drug candidates,” said TheraPsil CEO, Spencer Hawkswell.
The main objective of Project Solace is to help broaden legal access to psilocybin for Canadians plagued with end-of-life distress and other serious health afflictions when conventional treatment regimens have been unsuccessful.
The second goal is to develop a comprehensive body of evidence outlining clinical efficacy and experiential outcomes reported by clinicians and subjects from psilocybin-assisted psychotherapy provided through Health Canada’s Special Access Program, or under legal exemptions permitting possession of the compound — and overall safety.
TheraPsil says that Project Solace will initially assist patients in five primary regions and eventually expand as more treatment teams are onboarded. The non-profit will also be prescribing healthcare professionals with Current Good Manufacturing Practice (cGMP) psilocybin from licensed distributors participating in the campaign.
Data collected from the pilot project will be given to national regulatory organizations such as the Royal College of Physicians and Surgeons of Canada, Health Canada and the Canadian Institutes of Health Research (CIHR) in order to help simplify decision-making processes appertaining to future regulations of medical psilocybin.
“Project Solace represents an important opportunity to gain information regarding patient and clinician experiences with our drug candidates. Gathering this data will not only support our drug development program, it will also facilitate decision-making surrounding the regulatory system for the future of medicalized psilocybin,” said Filament Health CEO, Benjamin Lightburn.
Additional contributors of cGMP psilocybin for the project will include Psygen and HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP).
Photo via TheraPsil
